Automated and quantitative immunocytochemical assays of CD44v6 in breast carcinomas

Human Pathology

Volumn 28, Issue 3, 1997, Pages 289-296

  Charpin, Colette ^a,b   Garcia, Stéphane ^a   Bouvier, Corinne ^a   Devictor, Bénédicte ^a   Andrac, Lucile ^a   Choux, Régine ^a   Lavaut, Marie Noëlle ^a   Allasia, Claude ^a  

^a HÔPITAL NORD   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

Author keywords

automated immunocytochemistry; breast carcinomas; CD44v6; computerized image analysis

Indexed keywords

CD31 ANTIGEN; HERMES ANTIGEN; TUMOR MARKER;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BREAST CARCINOMA; FEMALE; FROZEN SECTION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMAGE PROCESSING; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; TUMOR DIFFERENTIATION; TUMOR GROWTH;

EID: 0031050188     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(97)90126-X     Document Type: Article

References (37)

1. Arch R, Wirth K, Hofmann M, et al: Participation in normal immune responses of a metastasis-inducing splicing variant of CD44. Science 257:682-685, 1992
2. Screaton GR, Bell MV, Jackson DG, et al: Genomic structure of DNA coding the lymphocyte homing reception CD44 reveals at least 12 alternatively spliced exons. Proc Nad Acad Sci U S A 89:12160-12164, 1992
3. Mackay CR, Terpe HJ, Stauder R, et al: Expression and modulation of CD44 variant isoforms in humans. J Cell Biol 124:71-82, 1994
4. Terpe HJ, Stark H, Prehm P, et al: CD44 variant isoforms are preferentially expressed in basal epithelia of non-malignant human fetal and adult tissues. Histochemistry 101:79-89, 1994
5. Sy MS, Guo YJ, Stamenkovic I: Distinct effects of two CD44 isoforms on tumor growth in vivo. J Exp Med 174:859-866, 1991
6. Günthert U, Hofmann M, Rudy W, et al: A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cells 65:13-24, 1991
7. Rudy W, Hofmann R, Schwartz-Albiez M, et al: Two major CD44 proteins expressed on a metastatic rat tumor cell line are derived from different splice variants: Each one individually suffices to confer metastatic behavior. Cancer Res 53:1262-1268, 1993
8. Seiter S, Arch R, Reber S, et al: Prevention of tumor metastasis formation by anti-variant CD44. J Exp Med 177:443-455, 1993
9. Koopman G, Heider KH, Horst E, et al: Activated human lymphocytes and aggressive non-Hodgkin's lymphomas express a homologue of the rat metastasis-associated variant of CD44. J Exp Med 177:897-904, 1993
10. Wielenga VJ, Heider K, Offerhaus JA, et al: Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res 53:4754-4756, 1993
11. Heider KH, Dammrich J, Skroch-Angel P, et al: Differential expression of CD44 splice variants in intestinal and diffuse-type human gastric carcinomas and normal gastric mucosa. Cancer Res 53:4197-4203, 1993
12. Fox SB, Gatter KC, Jackson DG, et al: CD44 and cancer screening. Lancet 342:548-549, 1993
13. Fox SB, Fawcett J, Jackson DG, et al: Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms. Cancer Res 54:4539-4546, 1994
14. Fujita N, Yaegashi N, Ide Y, et al: Expression of CD44 in normal human versus tumor endometrial tissues: Possible implication of reduced expression of CD44 in lymph-vascular space involvement of cancer cells. Cancer Res 54:3922-3928, 1994
15. Cannistra SA, Abu-Jawdeh G, Niloff J, et al: CD44 variant expression is a common feature of epithelial ovarian cancer: Lack of association with standard prognostic factors. J Clin Oncol 13:1912-1921, 1995
16. Hong RL, Pu YS, Hsieh TS, et al: Expressions of E-cadherin and exon V6-containing isoforms of CD44 and their prognostic values in human transitional cell carcinoma. J Urol 153:2025-2028, 1995
17. Guttinger M, Sutti F, Barnier C, et al: Expression of CD44 standard and variant forms in skin tumors loss of CD44 correlates with aggressive potential. Eur J Dermatol 5:398-406, 1995
18. Manten-Horst E, Danen EHJ, Smit L, et al: Expression of CD44splice variants in human cutaneous melanoma and melanoma cell lines is related to tumor progression and metastatic potential. Int J Cancer 64:182-188, 1995
19. Joensuu H, Klemi PJ, Toikkanen S, et al: Glycoprotein CD44 expression and its association with survival in breast cancer. Am J Pathol 143:687-874, 1993
20. Matsumura Y, Tarin D: Significance of CD44 gene products for cancer diagnosis and disease evaluation. Lancet 340:1053-1058, 1992
21. Abbasi AM, Chester KA, Talbot IC, et al: CD44 is associated with proliferation in normal and neoplastic human colorcctal epithelial cells. Eur J Cancer 29:1995-2002, 1993
22. Iida N, Bourguignon LYW: New CD44 splice variants associated with human breast cancers. J Cell Physiol 162:127-133, 1995
23. Kaufmann M, Heider KH, Sinn HP, et al: CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet 345:615-619, 1995
24. Friedrichs K, Kügler G, Franke F, et al: CD44 isoforms in prognosis of breast cancer. Lancet 345:1237, 1995
25. Dall P, Heider KH, Sinn HP, et al: Comparison of immuno-histochemistry and RT-PCR for detection of CD44v-expression: A new prognostic factor in human breast cancer. Int J Cancer 60:471-477, 1995
26. Bloom HJG, Richardson WW: Histological grading and prognosis in breast cancer. Br J Cancer 11:359-377, 1957
27. Le Doussal V, Tubiana-Hulin M, Friedman S, et al: Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR) : An improved score modification based on a multi-variate analysis of 1262 invasive ductal breast carcinomas. Cancer 64:1914-1921, 1989
28. Galea MH, Blarney RW, Elston CE, et al: The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 22:207-219, 1992
29. Charpin C, Martin P, Devictor B, et al: Multiparametric study (SAMBA 200) of estrogen receptor immunocytochemical assay in 400 human breast carcinomas analysis of estrogen receptor distribution heterogeneity in tissues and correlations with dextran coated charcoal assays and morphological data. Cancer Res 48:1578-1586, 1988
30. Charpin C, Jacquemier J, Andrac L, et al: Multiparametric analysis (SAMBA 200) of the progesterone receptor immunocytochemical assay in nonmalignant and malignant breast isorders. Am J Pathol 132:199-211, 1988
31. Charpin C, Andrac L, Vacheret H, et al: Multiparametric evaluation (SAMBA) of growth fraction (monoclonal Ki67) in breast carcinoma tissue sections. Cancer Res 48:4368-4374, 1988
32. Charpin C, Bonnier P, Devictor B, et al: Immunodetection of Her-2/neu protein in frozen sections evaluated by image analysis: Correlation with overall and disease-free survival in breast carcinomas. Anticancer Res 13:603-612, 1993
33. Charpin C, Devictor B, Andrac L, et al: p53 Quantitative immunocytochemical analysis in breast carcinomas. HUM PATHOL 26:159-166, 1995
34. Charpin C, Vielh P, Duffaud F, et al: Quantitative immunocytochemical assays of P-glycoprotein in breast carcinomas: Correlation to messenger RNA expression and to immunohistochemical prognostic indicators. J Natl Cancer Inst 86:1539-1545, 1994
35. Charpin C, Pellissier JF: Marqueurs moléculaires dans les cancers du sein: Aspect pratique et évaluation morphologique. Bull Acad Natl Méd 178:475-493, 1994
36. Grogan TM, Casey TT, Miller PC: Automation of immunohistochemistry. Adv Pathol Lab Med 6:253-283, 1993
37. Brugal G, Garbay C, Giroud-Adhel D: A double scanning microphotometer for image analysis: Hardware, software and biomedical application. J Histochem Cytochem 27:144, 1979